GLP-1 weight-loss calculator: understand historical trial averages
Translate selected STEP 1 and SURMOUNT-1 average percentage changes into pounds or kilograms. These historical group results are context for a conversation, not a personal prediction or a medication recommendation.
Last editorially updated: · By Jeff Schaeffer
Not medical advice. Talk to your prescriber and pharmacist. Confirm your prescribed dose, product, concentration, device, and instructions before using any calculation. This website cannot choose or change your treatment.
Translate trial averages into pounds or kilograms
—
Historical group averages, not an individual forecast or a dose recommendation.
How this is calculated: every formula is written out on this page, the sources are listed at the bottom, and our editorial policy explains how we check and correct numbers.
Comparing GLP-1 program costs?
Use your actual provider quote to estimate the full cost with our cost calculator. You can also review pricing and eligibility directly with a telehealth provider.
SkinnyRxOral and injectable GLP-1 options, with financing.See SkinnyRx options →Disclosure: GLP1 Math may earn a commission if you sign up through these links. It costs you nothing extra and does not change what the calculators show. A provider listing is not a medical recommendation.
What a trial-average calculation can tell you
A percentage can be difficult to picture in everyday terms. This calculator multiplies a starting weight by an average percentage reported in a specific trial arm, then subtracts that amount to show the corresponding ending weight. It answers a narrow mathematical question: what would that percentage look like at this starting weight? It does not estimate your probability of reaching the average, predict a weekly trajectory, select a medicine, or choose a maintenance dose. Those questions need information the tool does not collect and evidence this simple calculation does not provide.
The available options deliberately name the trial and studied amount. They are historical reference points, not a list of all currently approved regimens. Current product labels may include additional indications, presentations, or doses. For example, the present Wegovy label contains options beyond the 2.4 mg injection studied in STEP 1. The calculator does not extrapolate that trial's result to a different regimen or invent a percentage for a newer dose. Follow the linked prescribing information and discuss applicability with your clinician.
The two studies behind the options
STEP 1 enrolled 1,961 adults with overweight or obesity and without diabetes. It studied weekly semaglutide 2.4 mg alongside lifestyle intervention over 68 weeks. The reported average body-weight change used here is a 14.9% reduction, compared with 2.4% in the placebo group. The source is the original trial report indexed on PubMed, not an advertisement or a compilation of patient anecdotes. The result describes the studied population and intervention; it does not guarantee the same outcome for every person using semaglutide.
SURMOUNT-1 enrolled 2,539 adults with overweight or obesity and without diabetes. Over 72 weeks, the reported average reductions used here were 15.0% with tirzepatide 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg; placebo averaged 3.1%. Lifestyle intervention accompanied treatment. These trial arms are shown separately because replacing them with one universal tirzepatide percentage would erase an important part of the study design. The figures are not instructions to pursue the highest studied amount.
Work the arithmetic before interpreting the number
Suppose a hypothetical starting weight is 200 lb. Applying the STEP 1 average gives 200 × 0.149 = 29.8 lb of change. Subtracting that from 200 gives 170.2 lb. For a hypothetical 100 kg starting weight, the same percentage corresponds to 14.9 kg and an ending weight of 85.1 kg. The percentage is independent of the chosen weight unit as long as you use the same unit throughout. These examples illustrate multiplication and subtraction, not expected results for a real individual.
For comparison, applying a 20.9% study average to 200 lb gives 41.8 lb of change and 158.2 lb remaining. That arithmetic difference from another trial average is easy to calculate, but interpreting it as the treatment advantage you personally would obtain would go beyond the evidence displayed. The people, trial duration, adherence, and study circumstances were not identical. The tool shows source-specific scenarios side by side in a selector; it does not perform a head-to-head comparative-effectiveness analysis.
An average is not a target or a probability
People in a group can have different outcomes while sharing one mean. Some participants lose more than the average, some less, and some discontinue treatment. A single average cannot tell you how broad the distribution was, where you fall in it, or whether an outcome is appropriate for your health. This tool does not display a confidence interval or probability curve because it does not implement a validated individualized prediction model. A precise-looking output would not make those missing features appear.
A clinician may assess goals beyond body weight, including the condition being treated, treatment tolerance, nutrition, function, and other measures relevant to your care. Do not increase an amount or accelerate a schedule because the calculator's number seems appealing. Do not treat a slower personal change as proof that treatment has failed. Bring the actual course of treatment and your concerns to the prescriber. The distinction between arithmetic context and a clinical goal is central to using this page responsibly.
Why the result is not a weekly countdown
Dividing the total average loss by 68 or 72 produces an arithmetic rate, but it does not reproduce the shape of an actual treatment course. Dose escalation, interruptions, changes in eating patterns, and individual response can make progress uneven. The site therefore does not draw a straight-line forecast to a promised goal date. It shows the study length so readers understand the endpoint rather than mistaking a many-month trial result for an early-treatment expectation.
A weight recorded at an arbitrary week is also not directly comparable with a study endpoint without considering when treatment began, which regimen was followed, and what the trial measured. Keep a consistent record if your clinician recommends tracking, and bring questions about unexpected changes to them. The schedule page explains the difference between early label checkpoints and an individual treatment plan. It cannot make a current measurement comparable to a trial by assigning a dose step.
Population and product boundaries matter
The two selected trials excluded diabetes, so their displayed averages should not be presented as a diabetes-specific prediction. They are also not pediatric predictions, pregnancy guidance, or evidence for an unapproved mixture. A result from a branded trial does not establish that a compounded product has been reviewed by FDA for equivalent safety, effectiveness, or quality. Our brand and compounding guide explains that distinction without assuming a mathematical conversion can resolve it.
Using a different route, formulation, or schedule changes the question further. Oral and injectable products should not be combined into one generic semaglutide percentage. Likewise, a person moving from one medicine to another is not simply beginning the same trial scenario with a different button selected. The calculator cannot account for previous treatment or prescribe a switch. It is intentionally limited to showing what the named historical percentages mean in familiar weight units.
Put practical questions beside the trial result
Ask your prescriber which outcomes are relevant to your situation, how they will evaluate response, and what symptoms or difficulties should prompt contact. Ask your pharmacy about the exact product's storage, device training, and refill plan. Missed-dose instructions vary by product and are not calculated from weight-loss percentages. The label guide keeps those rules separate. If your measurement method involves a vial, a pharmacist must confirm concentration and syringe markings independently of any weight scenario.
Finally, use the cost calculator to understand a verified financial plan rather than assuming a predicted weight endpoint determines how many fills you need. This site cannot tell you when to stop treatment or how long benefits will persist after stopping. Trial arithmetic, treatment duration, and affordability are related discussion topics, but they are not interchangeable decisions. The useful outcome of this calculator is a clearer question for your clinician, supported by a named source and visible math.
Frequently asked questions
Will I lose the displayed amount?
The calculator cannot predict that. It applies a historical group average to your entered weight. Individual response and the suitability of a regimen require a clinical assessment. The output is a mathematical scenario, not a probability or promise.
Are these two studies a head-to-head comparison?
No. STEP 1 and SURMOUNT-1 were separate trials with different study durations and participants. Placing their averages in one tool helps explain the numbers but does not convert them into a randomized direct comparison between medicines.
Why are there no week-by-week forecasts?
A straight line from baseline to an average endpoint would imply a trajectory the calculator has not established. Weight change can vary over time. The site shows the original endpoint length without pretending it knows an individual course.
Can I enter kilograms?
Yes. Select kg and enter the starting weight in kilograms. The percentage calculation is the same, and both the change and ending-weight scenario remain in kilograms. Do not enter pounds while leaving kilograms selected.
Does a larger percentage mean I should choose that dose?
No. Dose selection depends on the product label, indication, response, tolerability, and prescriber judgment. A study average is not a treatment instruction, and the highest listed trial amount is not automatically appropriate.
Does this estimate compounded or oral treatment results?
No. The options refer to specific historical weekly injection trial arms. This page does not establish equivalent outcomes for compounded formulations, oral products, other regimens, or populations outside those trials.